Janux Therapeutics, Inc. (JANX)
Nasdaq: JANX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Who owns Janux Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
RA Capital Management, L.P. holds 19.9% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Mar 10, 2025 says.
Directors and officers
19
report now, of 32 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Mar 10, 2025 · Common Stock, par value $0.001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 28, 2026 · Common Stock · 5.7% in Jul 17, 2025
W. Lawrence Hawkins
SCHEDULE 13G · filed Feb 6, 2026 · Common Stock, $0.001 par value per share
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 6% in Feb 14, 2025
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 12, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.31% in Feb 12, 2025
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · reported falling below 5%, from 5.8% in Jan 8, 2026
State Street Corporation
SCHEDULE 13G · filed May 12, 2026 · COMMON STOCK · reported falling below 5%, from 6.4% in Feb 9, 2026
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5% in Apr 29, 2026
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · reported falling below 5%, from 6.9% in May 15, 2026
What JANX reports owning in othersstakes of 5% or more, and other ties
Janux Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
12sales
0purchases
4sales on a scheduled plan
7people selling
$1.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 36 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer | 5 | $700,000 | 4 | 0 | $0 |
| Campbell David Alan | President and CEO | 1 | $100,000 | 0 | 0 | $0 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | 1 | $100,000 | 0 | 0 | $0 |
| Dobek Maria | Vice President, Accounting | 2 | $0 | 0 | 0 | $0 |
| Diraimondo Thomas | Chief Scientific Officer | 1 | $0 | 0 | 0 | $0 |
| Mciver Zachariah | Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |
| Winter Charles M. | Chief Technical Officer | 1 | $0 | 0 | 0 | $0 |